Novavax is a biotechnology company focused on developing innovative vaccines to address a broad range of infectious diseases. Utilizing proprietary recombinant nanoparticle vaccine technology, Novavax creates vaccine candidates that efficiently respond to both known and emerging disease threats. The company also develops immune-stimulating saponin-based adjuvants through its wholly-owned Swedish subsidiary, Novavax AB, which enhance immune responses and have been well tolerated in multiple clinical trials. Novavax primarily serves global healthcare markets, including governments and healthcare providers, aiming to mitigate urgent public health crises such as pandemics. The business model revolves around research and development, clinical trials, and large-scale manufacturing of vaccine antigens and adjuvants, funded by partnerships and grants, such as those from CEPI. Revenue is generated through the sale of vaccines and adjuvants, as well as through licensing agreements and government contracts.

Keywords: biotechnology, vaccines, infectious diseases, nanoparticle technology, adjuvants, clinical trials, healthcare, pandemic response, global markets, CEPI funding.